Literature DB >> 8777863

Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis.

M Galeazzi, A M Bellucci, C R Girardelli, R Bono, O De Pita, P Puddu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8777863     DOI： 10.1007/bf02230347

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  12 in total

1.  Treatment of systemic vasculitis with pooled intravenous immunoglobulin.

Authors:  D R Jayne; M J Davies; C J Fox; C M Black; C M Lockwood
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

Review 2.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 3.  Down regulation of Fc receptors by IVIgG.

Authors:  J W Mannhalter; M M Eibl
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

Review 4.  Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses.

Authors:  F Rossi; G Dietrich; M D Kazatchkine
Journal:  Immunol Rev       Date:  1989-08       Impact factor: 12.988

5.  Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.

Authors:  P Cherin; S Herson; B Wechsler; J C Piette; O Bletry; A Coutellier; J M Ziza; P Godeau
Journal:  Am J Med       Date:  1991-08       Impact factor: 4.965

6.  Treatment of dermatomyositis with intravenous gammaglobulin.

Authors:  B A Lang; R M Laxer; G Murphy; E D Silverman; C M Roifman
Journal:  Am J Med       Date:  1991-08       Impact factor: 4.965

Review 7.  Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

Authors:  N Ronda; V Hurez; M D Kazatchkine
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

8.  Juvenile dermatomyositis: treatment with intravenous gammaglobulin.

Authors:  E Collet; S Dalac; B Maerens; J M Courtois; M Izac; D Lambert
Journal:  Br J Dermatol       Date:  1994-02       Impact factor: 9.302

9.  Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

Authors:  M Basta; P Kirshbom; M M Frank; L F Fries
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

10.  Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.

Authors:  F Rossi; D R Jayne; C M Lockwood; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330
View more
  4 in total

Review 1.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

2.  Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.

Authors:  Deborah M Levy; C April Bingham; Philip J Kahn; Andrew H Eichenfield; Lisa F Imundo
Journal:  J Pediatr       Date:  2009-10-28       Impact factor: 4.406

Review 3.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 4.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.